IBDEI2HB ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,39588,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39588,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
;;^UTILITY(U,$J,358.3,39588,1,4,0)
;;=4^C91.11
;;^UTILITY(U,$J,358.3,39588,2)
;;=^5001766
;;^UTILITY(U,$J,358.3,39589,0)
;;=C91.10^^152^2000^49
;;^UTILITY(U,$J,358.3,39589,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39589,1,3,0)
;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
;;^UTILITY(U,$J,358.3,39589,1,4,0)
;;=4^C91.10
;;^UTILITY(U,$J,358.3,39589,2)
;;=^5001765
;;^UTILITY(U,$J,358.3,39590,0)
;;=C92.11^^152^2000^50
;;^UTILITY(U,$J,358.3,39590,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39590,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
;;^UTILITY(U,$J,358.3,39590,1,4,0)
;;=4^C92.11
;;^UTILITY(U,$J,358.3,39590,2)
;;=^5001793
;;^UTILITY(U,$J,358.3,39591,0)
;;=C92.10^^152^2000^51
;;^UTILITY(U,$J,358.3,39591,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39591,1,3,0)
;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
;;^UTILITY(U,$J,358.3,39591,1,4,0)
;;=4^C92.10
;;^UTILITY(U,$J,358.3,39591,2)
;;=^5001792
;;^UTILITY(U,$J,358.3,39592,0)
;;=D47.1^^152^2000^52
;;^UTILITY(U,$J,358.3,39592,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39592,1,3,0)
;;=3^Chronic Myeloproliferative Disease
;;^UTILITY(U,$J,358.3,39592,1,4,0)
;;=4^D47.1
;;^UTILITY(U,$J,358.3,39592,2)
;;=^5002256
;;^UTILITY(U,$J,358.3,39593,0)
;;=C82.69^^152^2000^53
;;^UTILITY(U,$J,358.3,39593,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39593,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,39593,1,4,0)
;;=4^C82.69
;;^UTILITY(U,$J,358.3,39593,2)
;;=^5001530
;;^UTILITY(U,$J,358.3,39594,0)
;;=C82.60^^152^2000^54
;;^UTILITY(U,$J,358.3,39594,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39594,1,3,0)
;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
;;^UTILITY(U,$J,358.3,39594,1,4,0)
;;=4^C82.60
;;^UTILITY(U,$J,358.3,39594,2)
;;=^5001521
;;^UTILITY(U,$J,358.3,39595,0)
;;=D56.2^^152^2000^55
;;^UTILITY(U,$J,358.3,39595,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39595,1,3,0)
;;=3^Delta-Beta Thalassemia
;;^UTILITY(U,$J,358.3,39595,1,4,0)
;;=4^D56.2
;;^UTILITY(U,$J,358.3,39595,2)
;;=^340496
;;^UTILITY(U,$J,358.3,39596,0)
;;=D75.9^^152^2000^56
;;^UTILITY(U,$J,358.3,39596,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39596,1,3,0)
;;=3^Disease of Blood/Blood-Forming Organs,Unspec
;;^UTILITY(U,$J,358.3,39596,1,4,0)
;;=4^D75.9
;;^UTILITY(U,$J,358.3,39596,2)
;;=^5002393
;;^UTILITY(U,$J,358.3,39597,0)
;;=D59.0^^152^2000^59
;;^UTILITY(U,$J,358.3,39597,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39597,1,3,0)
;;=3^Drug-Induced Autoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,39597,1,4,0)
;;=4^D59.0
;;^UTILITY(U,$J,358.3,39597,2)
;;=^5002323
;;^UTILITY(U,$J,358.3,39598,0)
;;=D59.2^^152^2000^60
;;^UTILITY(U,$J,358.3,39598,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39598,1,3,0)
;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
;;^UTILITY(U,$J,358.3,39598,1,4,0)
;;=4^D59.2
;;^UTILITY(U,$J,358.3,39598,2)
;;=^5002325
;;^UTILITY(U,$J,358.3,39599,0)
;;=R59.9^^152^2000^63
;;^UTILITY(U,$J,358.3,39599,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,39599,1,3,0)
;;=3^Enlarged Lymph Nodes,Unspec
;;^UTILITY(U,$J,358.3,39599,1,4,0)
;;=4^R59.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI2HB 3745 printed Dec 13, 2024@02:28:44 Page 2
IBDEI2HB ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,39588,1,0)
+2 ;;=^358.31IA^4^2
+3 ;;^UTILITY(U,$J,358.3,39588,1,3,0)
+4 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
+5 ;;^UTILITY(U,$J,358.3,39588,1,4,0)
+6 ;;=4^C91.11
+7 ;;^UTILITY(U,$J,358.3,39588,2)
+8 ;;=^5001766
+9 ;;^UTILITY(U,$J,358.3,39589,0)
+10 ;;=C91.10^^152^2000^49
+11 ;;^UTILITY(U,$J,358.3,39589,1,0)
+12 ;;=^358.31IA^4^2
+13 ;;^UTILITY(U,$J,358.3,39589,1,3,0)
+14 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
+15 ;;^UTILITY(U,$J,358.3,39589,1,4,0)
+16 ;;=4^C91.10
+17 ;;^UTILITY(U,$J,358.3,39589,2)
+18 ;;=^5001765
+19 ;;^UTILITY(U,$J,358.3,39590,0)
+20 ;;=C92.11^^152^2000^50
+21 ;;^UTILITY(U,$J,358.3,39590,1,0)
+22 ;;=^358.31IA^4^2
+23 ;;^UTILITY(U,$J,358.3,39590,1,3,0)
+24 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
+25 ;;^UTILITY(U,$J,358.3,39590,1,4,0)
+26 ;;=4^C92.11
+27 ;;^UTILITY(U,$J,358.3,39590,2)
+28 ;;=^5001793
+29 ;;^UTILITY(U,$J,358.3,39591,0)
+30 ;;=C92.10^^152^2000^51
+31 ;;^UTILITY(U,$J,358.3,39591,1,0)
+32 ;;=^358.31IA^4^2
+33 ;;^UTILITY(U,$J,358.3,39591,1,3,0)
+34 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
+35 ;;^UTILITY(U,$J,358.3,39591,1,4,0)
+36 ;;=4^C92.10
+37 ;;^UTILITY(U,$J,358.3,39591,2)
+38 ;;=^5001792
+39 ;;^UTILITY(U,$J,358.3,39592,0)
+40 ;;=D47.1^^152^2000^52
+41 ;;^UTILITY(U,$J,358.3,39592,1,0)
+42 ;;=^358.31IA^4^2
+43 ;;^UTILITY(U,$J,358.3,39592,1,3,0)
+44 ;;=3^Chronic Myeloproliferative Disease
+45 ;;^UTILITY(U,$J,358.3,39592,1,4,0)
+46 ;;=4^D47.1
+47 ;;^UTILITY(U,$J,358.3,39592,2)
+48 ;;=^5002256
+49 ;;^UTILITY(U,$J,358.3,39593,0)
+50 ;;=C82.69^^152^2000^53
+51 ;;^UTILITY(U,$J,358.3,39593,1,0)
+52 ;;=^358.31IA^4^2
+53 ;;^UTILITY(U,$J,358.3,39593,1,3,0)
+54 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
+55 ;;^UTILITY(U,$J,358.3,39593,1,4,0)
+56 ;;=4^C82.69
+57 ;;^UTILITY(U,$J,358.3,39593,2)
+58 ;;=^5001530
+59 ;;^UTILITY(U,$J,358.3,39594,0)
+60 ;;=C82.60^^152^2000^54
+61 ;;^UTILITY(U,$J,358.3,39594,1,0)
+62 ;;=^358.31IA^4^2
+63 ;;^UTILITY(U,$J,358.3,39594,1,3,0)
+64 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
+65 ;;^UTILITY(U,$J,358.3,39594,1,4,0)
+66 ;;=4^C82.60
+67 ;;^UTILITY(U,$J,358.3,39594,2)
+68 ;;=^5001521
+69 ;;^UTILITY(U,$J,358.3,39595,0)
+70 ;;=D56.2^^152^2000^55
+71 ;;^UTILITY(U,$J,358.3,39595,1,0)
+72 ;;=^358.31IA^4^2
+73 ;;^UTILITY(U,$J,358.3,39595,1,3,0)
+74 ;;=3^Delta-Beta Thalassemia
+75 ;;^UTILITY(U,$J,358.3,39595,1,4,0)
+76 ;;=4^D56.2
+77 ;;^UTILITY(U,$J,358.3,39595,2)
+78 ;;=^340496
+79 ;;^UTILITY(U,$J,358.3,39596,0)
+80 ;;=D75.9^^152^2000^56
+81 ;;^UTILITY(U,$J,358.3,39596,1,0)
+82 ;;=^358.31IA^4^2
+83 ;;^UTILITY(U,$J,358.3,39596,1,3,0)
+84 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
+85 ;;^UTILITY(U,$J,358.3,39596,1,4,0)
+86 ;;=4^D75.9
+87 ;;^UTILITY(U,$J,358.3,39596,2)
+88 ;;=^5002393
+89 ;;^UTILITY(U,$J,358.3,39597,0)
+90 ;;=D59.0^^152^2000^59
+91 ;;^UTILITY(U,$J,358.3,39597,1,0)
+92 ;;=^358.31IA^4^2
+93 ;;^UTILITY(U,$J,358.3,39597,1,3,0)
+94 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
+95 ;;^UTILITY(U,$J,358.3,39597,1,4,0)
+96 ;;=4^D59.0
+97 ;;^UTILITY(U,$J,358.3,39597,2)
+98 ;;=^5002323
+99 ;;^UTILITY(U,$J,358.3,39598,0)
+100 ;;=D59.2^^152^2000^60
+101 ;;^UTILITY(U,$J,358.3,39598,1,0)
+102 ;;=^358.31IA^4^2
+103 ;;^UTILITY(U,$J,358.3,39598,1,3,0)
+104 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
+105 ;;^UTILITY(U,$J,358.3,39598,1,4,0)
+106 ;;=4^D59.2
+107 ;;^UTILITY(U,$J,358.3,39598,2)
+108 ;;=^5002325
+109 ;;^UTILITY(U,$J,358.3,39599,0)
+110 ;;=R59.9^^152^2000^63
+111 ;;^UTILITY(U,$J,358.3,39599,1,0)
+112 ;;=^358.31IA^4^2
+113 ;;^UTILITY(U,$J,358.3,39599,1,3,0)
+114 ;;=3^Enlarged Lymph Nodes,Unspec
+115 ;;^UTILITY(U,$J,358.3,39599,1,4,0)
+116 ;;=4^R59.9
